Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Kronična mieloična levkemija
Authors:ID Bokal, Urška (Author)
ID Južnič Šetina, Tanja (Author)
Files:.pdf PDF - Presentation file, download (273,85 KB)
MD5: 646D6119AA918583694953A054E94CA8
PID: 20.500.12556/dirros/f124865b-36ce-45a0-8252-d32a04522f7b
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Kronična mieloična levkemija (KML) je redka mieloproliferativna bolezen z incidenco okrog 1–2/100.000 prebivalcev na leto. Je klonska bolezen pluripotentne matične celice, usmerjene v granulopoezo. Večino bolnikov odkrijemo v kroničnem obdobju, za katero je značilna levkocitoza v krvni sliki, s prevladovanjem zrelih nevtrofilnih granulocitov, znaki pospešene presnove, kot so utrujenost, hujšanje in potenje, ter splenomegalija. Kronično obdobje prek pospešenega obdobja preide v blastno krizo s sliko akutne levkemije. Za postavitev diagnoze je nujna najdba kromosoma Philadelphia, ki nastane kot posledica kromosomske translokacije t(9;22), gena BCR-ABL ali njegovega produkta tirozinske kinaze BCR- -ABL v celicah periferne krvi ali kostnega mozga. Velik napredek pri zdravljenju KML je bilo odkritje zaviralcev tirozinske kinaze BCR-ABL, s katerimi dosežemo dolgotrajen nadzor bolezni, in sicer z imatinibom kot prvo izbiro zdravljenja kroničnega obdobja KML. Drugi možni izbiri zdravljenja sta alogenična presaditev krvotvornih matičnih celic in paliativno zdravljenje s kemoterapevtiki.
Publication status:Published
Publication version:Version of Record
Year of publishing:2012
Number of pages:str. 10-13, 57
Numbering:Letn. 16, št. 1
PID:20.500.12556/DiRROS-8843 New window
UDC:616.15-006.6-07-08
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-LVB65VWB
COBISS.SI-ID:1319547 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:4140
Downloads:916
Metadata:XML DC-XML DC-RDF
:
BOKAL, Urška and JUŽNIČ ŠETINA, Tanja, 2012, Kronična mieloična levkemija. Onkologija [online]. 2012. Vol. 16, no. 1, p. 10–13, 57. [Accessed 1 April 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=8843
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Chronic myelogenous leukemia
Abstract:Chronic myelogenous leukemia (CML) is a rare myeloproliferative disease with an incidence of approximately 1-2/100,000 population per year. It is a clonal disease of a pluripotent stem cell committed to granulopoiesis. Most patients are diagnosed in the chronic phase when the blood count typically shows leukocytosis with predominance of mature neutrophil granulocytes and there are evident signs of increased metabolism, such as fatigue, weight loss and perspiration, and splenomegaly. Through the accelerated phase, the chronic phase progresses to a blast crisis resembling acute leukemia. The diagnosis is based on the discovery of the Philadelphia chromosome arising as a consequence of chromosomal translocation t(9;22), BCRABL gene or its product, BCR-ABL tyrosine kinase, in the peripheral blood or bone marrow cells. Significant progress in the treatment of CML was accomplished by the discovery of the BCR-ABL tyrosine kinase inhibitors, which provide long-term disease control, namely with imatinib as the first choice of treatment in the chronic phase of CML. The other two possible treatments are the allogeneic transplantation of haematopoietic stem cells and palliative treatment with chemotherapeutics.


Archive

niGradiv

Back